gimli

KPL stock AI analysis

KPL Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

KWALITY PHARMACEUTICALS L is a small-cap stock in Healthcare. This Gimli page shows the latest available KPL price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Analyze with AI Open interactive KPL stock page

Price

₹3,471.20

1W return

-1.15%

1M return

-1.74%

3M return

+48.18%

6M return

n/a

1Y return

n/a

Market cap

₹n/a

n/a

ROE

+27.37%

ROCE

+19.31%

RSI

55.29

Turnover

₹9.95 cr

Why it can matter in screens

Momentum: KPL is above 50DMA, below 200DMA; RSI is 55.29.
Returns: 1D +0.55%, 1W -1.15%, 1M -1.74%, 3M +48.18%, 1Y n/a.
Trend levels: 52W high ₹3,798.90, 52W low ₹2,180.00, off high -8.63%.
Liquidity: latest turnover is ₹9.95 cr; volume vs 20D is +0.63%.
Valuation/profitability: PE n/a, PB n/a, ROE +27.37%, ROCE +19.31%.
Growth: 3Y sales CAGR +25.59%, 3Y profit CAGR +51.22%.

Quick Answers

What is the latest KPL stock price?

The latest stored price for KPL is Rs 3,471.20 as of 2026-09-18.

Is KPL above its 50DMA and 200DMA?

KPL is above 50DMA, below 200DMA. The latest 50DMA is 3,095.09 and the latest 200DMA is n/a.

What are KPL PE, ROE and ROCE?

KPL has PE n/a, ROE +27.37%, and ROCE +19.31% in Gimli's latest available snapshot.

How has KPL performed recently?

KPL has returned -1.74% over 1 month, +48.18% over 3 months, and n/a over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-06-30	162.97 cr	41.64 cr	25.63 cr	24.70
2026-03-31	158.17 cr	39.82 cr	25.31 cr	24.39
2025-12-31	123.97 cr	30.48 cr	16.00 cr	15.42
2025-09-30	111.95 cr	26.25 cr	14.12 cr	13.60
2025-06-30	111.86 cr	24.55 cr	11.92 cr	11.49
2025-03-31	115.68 cr	26.65 cr	14.49 cr	n/a

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	503.06 cr	120.27 cr	67.35 cr	n/a
2025-03-31	372.12 cr	82.36 cr	39.89 cr	38.44
2024-03-31	309.00 cr	61.36 cr	23.98 cr	23.11
2023-03-31	253.94 cr	46.70 cr	19.47 cr	18.45
2022-03-31	459.64 cr	175.24 cr	120.05 cr	115.36

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	592.21 cr	0.74 cr	130.70 cr	329.92 cr
2025-03-31	447.27 cr	12.02 cr	112.45 cr	262.40 cr
2024-03-31	394.21 cr	2.26 cr	98.12 cr	222.58 cr
2023-03-31	353.63 cr	3.07 cr	90.26 cr	199.07 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	16.59 cr	-32.35 cr	n/a
2025-03-31	52.72 cr	27.72 cr	n/a
2024-03-31	42.98 cr	13.14 cr	n/a
2023-03-31	41.38 cr	-6.29 cr	n/a
2022-03-31	n/a	n/a	n/a

Shareholding Trend

No recent data available.

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	440,829.82 cr	36.388220	+15.50%	+11.45%
DIVISLAB	DIVI S LABORATORIES LTD	248,876.81 cr	85.407280	+18.37%	+53.39%
TORNTPHARM	TORRENT PHARMACEUTICALS L	163,807.57 cr	75.106636	+17.33%	+35.67%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	128,608.22 cr	65.670049	+21.03%	+13.94%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	116,723.14 cr	26.011308	+16.04%	+10.70%
CIPLA	CIPLA LTD	112,647.78 cr	33.401961	+10.25%	-11.64%
LAURUSLABS	LAURUS LABS LIMITED	105,487.98 cr	96.587446	+21.77%	+111.64%
MAXHEALTH	MAX HEALTHCARE INS LTD	102,122.47 cr	70.799892	+14.33%	-10.58%

Try these prompts

Analyze KWALITY PHARMACEUTICALS L with valuation, momentum and industry peers
Compare KPL with other Healthcare stocks
Show small-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-09-18. Not investment advice.